15:58:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-15 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning PAX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-02-23 Bokslutskommuniké 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Ordinarie utdelning PAX 0.00 SEK
2023-05-24 Kvartalsrapport 2023-Q1
2023-05-24 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-27 Ordinarie utdelning PAX 0.00 SEK
2022-05-25 Kvartalsrapport 2022-Q1
2022-05-25 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning PAX 0.00 SEK
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-26 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning PAX 0.00 SEK
2020-05-27 Årsstämma 2020
2020-05-27 Kvartalsrapport 2020-Q1
2020-02-21 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning PAX 0.00 SEK
2019-05-23 Årsstämma 2019
2019-05-23 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning PAX 0.00 SEK
2018-05-24 Kvartalsrapport 2018-Q1
2018-05-24 Årsstämma 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Paxman är verksamt inom skalpkylning, som används för patienter som behandlas för cytostatika. Bolagets produkt Paxman Scalp Cooler används för att minimera håravfallet hos patienten under behandlingens gång. Scalp Coolern är en fristående, mobil och eldriven kylenhet som kyler ner patientens hårbotten via en kylmössa. Paxman grundades 1996 och har idag sitt huvudkontor i Karlshamn.
2021-12-21 13:00:00

Today, Paxman publishes the December issue of its newsletter aimed at shareholders, investors and other interested parties.

This month’s issue highlights Paxman’s directed share issue of 1,400,000 shares to existing and new shareholders, including including Creades AB (publ), Alcur Fonder and Andra AP-fonden. The proceeds from the share issue will be used to to strengthen the company’s financial position and the continued work to execute on its commercialisation strategy, including the launch of a new buy-and-bill business model in the United States to enable reimbursement.

The newsletter also includes information on "Knowledge Transfer Partnership” (KPT), a new collaboration between Paxman and the University of Huddersfield to develop a novel medical device for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) with financing from Innovate UK, several received orders for upgrades and new installations in the US, Europe, Asia and the Middle East, and that Paxman Scalp Cooling has been included in the new generation of an innovative mobile cancer care concept developed by the British charity Hope for Tomorrow.

To read the newsletter and subscribe for upcoming issues, follow this link:

https://bit.ly/paxdec21en

Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.